Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.66 | N/A | -468.97% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.66 | N/A | -468.97% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding the company's performance amid ongoing market challenges. They did not provide specific guidance for future quarters.
Management did not provide specific insights into revenue expectations.
The company acknowledged challenges in the current market environment.
Veracyte's earnings report showed a significant miss on EPS, which contributed to a 4.6% drop in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's future performance. Overall, the cautious tone from management suggests that the company is navigating a challenging environment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
UBIQUITI INC
May 7, 2021